The TRIUMPH-4 Phase 3 trial, completed in late 2025, delivered equally striking results
GLP-1 receptor activation slows gastric emptying, which can cause variable bowel changes including looser stools, diarrhoea, or constipation
Short-acting GLP-1RAs, such as lixisenatide, maintain robust effects on gastric emptying, whereas long-acting agents, like liraglutide and semaglutide, exhibit reduced efficacy due to continuous receptor activation
Not just nausea Another side effect of GLP-1 drugs is a decrease in thirst, which could be dangerous for people who are already losing lots of fluids from side effects like vomiting and diarrhea
What Is Shed GLP-1
All available GLP-1 therapy relies on established injectable formulations such as semaglutide, dulaglutide, and liraglutide, which have extensive clinical evidence supporting their use